Breaking News: Frontline Nivolumab Approved for Melanoma

Breaking News: Frontline Nivolumab Approved for Melanoma

Episodes

Specialty:

All

Year:

All

EP. 1: FDA Approves First-Line Nivolumab for Advanced Melanoma

November 24th 2015

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors